Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA: Fee Avoidance Affects Rates Again

Executive Summary

Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.

You may also be interested in...



Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.

Generic User Fee Hikes Could Disrupt US FDA Drug Pricing Campaign

New GDUFA program fee is high enough that sponsors may withdraw applications to reduce their fee exposure, agency estimates.

Generic User Fee 'Relief' For Small Firms Would Mean Bigger Bills For Large One

Talks between industry and FDA focus on size of the discount and how a small business would be defined.

Related Content

Topics

UsernamePublicRestriction

Register

PS055539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel